Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Ovarian Cancer Metastatic × fludarabine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 29 Leukemia 23 Lymphoma, Non-Hodgkin 22 Lymphoma 22 Precursor Cell Lymphoblastic Leukemia-Lymphoma 19 Leukemia, Lymphocytic, Chronic, B-Cell 18 Myelodysplastic Syndromes 17 Hematologic Neoplasms 17 Melanoma 15 Lymphoma, B-Cell 14 Recurrence 12 Multiple Myeloma 12 Neoplasm Metastasis 11 Hodgkin Disease 11 Pancreatic Neoplasms 9 Ovarian Neoplasms 8 Lymphoma, Large B-Cell, Diffuse 8 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8 Breast Neoplasms 8 Stomach Neoplasms 7 Lymphoma, Mantle-Cell 7 Lymphoma, Follicular 7 Uterine Cervical Neoplasms 6 Carcinoma, Non-Small-Cell Lung 6 Neoplasms 5 Burkitt Lymphoma 5 Neoplasms, Plasma Cell 4 Myeloproliferative Disorders 4 Lymphoproliferative Disorders 4 Lung Neoplasms 4

Interventions

fludarabine 1 aldesleukin 1 Interleukin-2 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04389229 2020-12-16

OVSTAR

Immetacyte Ltd

Phase 1/2 Withdrawn

Ovarian Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡